Ajax Therapeutics presents AJX-101 trial results at EHA2026

Sus Clinicals is ensuring we change the way we do preclinical oncology. As AACR comes to a close, we presented two posters showcasing our innovative approach. Traditionally, efficacy studies are conducted in mice, while safety assessments are performed in dogs or non-human primates. However, we propose a single model that encompasses the disease state for comprehensive testing. Introducing our mini oncopig: this model allows us to evaluate safety, efficacy, metabolism, and distribution all in one. For those familiar with my work, you know my commitment to revolutionizing the drug development process. Our ultimate goal is to enhance the journey of getting drugs to the clinic, always with the patients we serve in mind. Join us for our webinar tomorrow, where Kyle and Matt will share practical applications of our Oncopig.

TriSalus Life Sciences (NASDAQ: TLSI) has initiated patient enrollment for its PREDICTT clinical trial designed to evaluate its novel Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic liver tumors. https://lnkd.in/eNXgVae4

Oncology KOLs react to the exciting FDA approval based on the DESTINY-Breast11 (and DESTINY-Breast05) clinical trials. 👉AI-Native web page, Use as a source in NotebookLM! https://hubs.ly/Q04gTzS00

Compass's COMPANION-002 just confirmed a sealed verdict 540 days in the making. Eighteen months ago, an independent BVCT head-to-head — Tovecimig + paclitaxel vs paclitaxel monotherapy in 2L+ advanced biliary tract cancer — was sealed on 3 November 2024 (No. 1195), run from outside the sponsor's data against the publicly registered protocol NCT05506943 at https://lnkd.in/gHXX2ZzQ. The sealed verdict: PFS wins on the primary endpoint; OS non-superior to paclitaxel alone; intra-tumoral DLL4 expression flagged as the crucial OS stratification differentiator. Last week, COMPANION-002 confirmed it line for line: PFS HR 0.44, p<0.0001 on the primary endpoint, OS HR 1.05 in the unstratified arm. This is the tenth sealed BVCT run on PFS–OS discordance, and the tenth time the readout matched. Average lead across the ten: 284 days. Drug MoA + publicly registered protocol only. Your patient data stays yours. For every Phase 2/3 advancement gate that carries a PFS–OS discordance question — the answer can sit on a sealed prospective record before the readout arrives. The case of record now spans ten. See the proof at https://lnkd.in/eFV9DdKs. Clinically all-seeing before decisions. Earlier BVCT is kinder for patients. #BioinvestGPT #VirtualClinicalTrial #ProspectivePrediction #BiliaryTractCancer #DrugDevelopment #ClinicallyAllSeeing

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda. #pharma #earnings #biospace https://hubs.li/Q04f6BPN0

FOCUS on PROTACs. On May 1st the first PROTAC, a heterobifunctional protein degrader, and a new therapeutic modality, was approved by the FDA. Vepdegestrant (Arvinas' Veppanu) has been approved as a treatment for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. "This milestone demonstrates that targeted protein degradation can translate into meaningful clinical impact". Arvinas Press Release https://lnkd.in/e9AF77j8 FDA announcement https://lnkd.in/eU-JB9HC FOCUS Biomolecules can supply Vepdegestrant (ARV-471) for research applications. Contact us for more info https://lnkd.in/dG8wyUz6 #Smallmolecules #Cancerresearch #PROTAC #Pharmacology

Gilead Sciences and Arcus Biosciences are discontinuing Phase 3 STAR-121 domvanalimab NSCLC study due to futility, triggering broader rollback of their TIGIT collaboration, underscoring ongoing setbacks in the TIGIT immuno-oncology class. The outcome highlights continued uncertainty in novel checkpoint targets beyond PD-1/PD-L1 and reinforces how late-stage failures can rapidly reshape partnership structures and portfolio prioritization in oncology pipelines even after earlier mid-stage signals of activity. This underscores how translational risk remains high in immune-oncology, particularly when early signals fail to replicate in confirmatory trials. Follow this page for more insights, updates, and perspectives on healthcare and life sciences. https://lnkd.in/g74uUb6Y

We will be presenting data on POLB 001 at the European Hematology Association (EHA) Congress, one of the world’s leading scientific meetings focused on haematology. The abstract outlines further evidence of POLB 001’s potential to prevent cancer immunotherapy-induced CRS: 🔵In vivo models showing the capacity of POLB 001 to reduce multiple key CRS-related cytokines (including TNF, IFNγ, and IL-6) 🔵In vitro data showing that POLB 001 can inhibit cytokine production without impairing bispecific antibody-induced tumour cell killing Title: POLB 001, an oral P38 MAPK Inhibitor for the Prevention of Cytokine Release Syndrome 📆Saturday, 13 June 2026, 18:45 - 19:45 CEST 📍Poster Session 2 If you are attending the conference and would like to schedule a meeting with the Company to learn more, please contact partnering@poolbegpharma.com. Learn more: https://lnkd.in/eNSsXKfr #POLB #ScientificPoster #ScientificData #EHA #EuropeanHematologyAssociationCongress

🎉 A new milestone met by NETRIS Pharma team! Our phase 1b LAPNET-01 trial results have just been published in @Nature — one of the most prestigious scientific journals in the world. 📄✨ 🔬 The study evaluated NP137, our first-in-class anti-netrin-1 monoclonal antibody, combined with mFOLFIRINOX as a first-line treatment for patients with locally advanced pancreatic ductal adenocarcinoma (LAPC) — one of the most difficult cancers to treat, with historically limited options for patients. The results are remarkable: 📈 Median progression-free survival: 10.85 months ⏱️ Median overall survival: 16.43 months 🏥 23% conversion-to-surgery rate And in the subgroup of patients with high neogenin expression (netrin-1 receptor), the numbers are even more striking: 🚀 Median PFS: 15.65 months 💯 12-month OS rate: 100% ⭐ 40% conversion-to-surgery rate Behind every data point are patients and families facing one of the toughest diagnoses in oncology. Seeing science translate into real hope for them is exactly why we do what we do. 🎗️ Huge congratulations to Patrick Mehlen, Founder and CEO of NETRIS Pharma, to Prof. Gael Roth, lead investigator and first author, to all the clinical teams, patients, and partners who made this possible — and to every single colleague at Netris Pharma who has contributed to this journey. 🙌 This is only the beginning. Onwards. 🚀 🔗 Read the full paper in Nature: https://lnkd.in/eGBCSuuk #Netrin1 #NP137 #PancreaticCancer #PDAC #Oncology #ClinicalResearch #Biotech #Innovation #Nature #innovative approaches

Most pharma and biotech companies entering rare disease or oncology are making high-stakes decisions with the wrong research. The FDA's own ARC Program recognises it: small patient pools, uncertain endpoints, and complex regulatory pathways make this space unlike any other. Generic market reports were never built for this. The pace isn't slowing down. In 2026 alone, the FDA has approved breakthrough therapies across rare mitochondrial disease, rare kidney disease, and now a first-in-class protein degrader in breast cancer each approval reshaping market dynamics overnight. The stakeholders who act on the right intelligence, at the right time, will define what comes next. That is exactly what Fyreignis Market Research is built for. #RareDisease #Oncology #StrategicAdvisory #MarketIntelligence #PharmaStrategy